None
Quote | Fulcrum Therapeutics Inc. (NYSE:FULC)
Last: | $ |
---|---|
Change Percent: | -3.21% |
Open: | $16.30 |
Close: | $15.68 |
High: | $16.30 |
Low: | $15.40 |
Volume: | 41,328 |
Last Trade Date Time: | 02/12/2020 04:43:03 pm |
News | Fulcrum Therapeutics Inc. (NYSE:FULC)
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.9% on the day to $7.74. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with gen...
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today ...
Message Board Posts | Fulcrum Therapeutics Inc. (NYSE:FULC)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $FULC 20% v1,358M c12.30 f52,051M H12.41 ML5.11 | znewcar1 | investorshangout | 01/10/2023 10:33:05 PM |
In some for a bounce play at $3.86 | ottoman | investorshub | 06/12/2022 5:03:11 PM |
what a great short today 25 bucks, just | NYCJR | investorshub | 08/11/2021 9:46:57 PM |
Also > The company reported $4.40 million in | crudeoil24 | investorshub | 08/10/2021 4:26:00 PM |
Way up premarket on sickle cell news. | axconth | investorshub | 08/10/2021 1:10:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.9% on the day to $7.74. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with gen...
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmac...
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today ...